Enzyme Blend for DOMS Symptom Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for delayed onset muscle soreness (DOMS) are limited in effectiveness and inconsistency due to absorption issues and a lack of understanding of the exact mechanism, failing to comprehensively address all symptoms.
Innovation Solution
A comprehensive digestive enzyme blend of Protease, Amylase, Lactase, and Lipase (DigeZyme) is administered to alleviate DOMS symptoms, with specific enzyme concentrations and a therapeutic management method for mammals experiencing muscle pain, tenderness, inflammation, and muscle damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional protease-based supplements are used for DOMS treatment, then some symptoms may be improved, but absorption issues and enzyme destruction in the gut limit effectiveness
Solution Approach 1:
The patent combines multiple digestive enzymes (protease, amylase, lipase, cellulase, lactase) into a single composite preparation. This merging approach ensures comprehensive digestion of various macronutrients simultaneously, improving overall absorption efficiency and preventing enzyme destruction issues that limit traditional single-enzyme treatments for DOMS.
Solution Approach 2:
The invention uses a composite enzyme preparation containing five different digestive enzymes rather than a single enzyme type. This composite material approach addresses the limitation of traditional protease-only supplements by providing a broader enzymatic profile that enhances absorption and effectiveness while reducing harmful factors associated with single-enzyme preparations.
2Device complexity
If single-enzyme (protease) supplements are used, then the treatment is simple, but the efficacy is limited and inconsistent
Solution Approach 1:
The patent merges five different digestive enzymes into one supplement formulation, maintaining simplicity of use while dramatically improving consistency of efficacy. The combined enzymes work synergistically to digest proteins, carbohydrates, fats, and other macronutrients, providing reliable and consistent DOMS treatment results that single-enzyme supplements cannot achieve.
Solution Approach 2:
The composite enzyme preparation performs multiple functions simultaneously - digesting proteins (protease), carbohydrates (amylase), fats (lipase), plant cell walls (cellulase), and dairy proteins (lactase). This multi-functionality ensures consistent and reliable treatment efficacy across diverse nutritional contexts, overcoming the limitations of single-enzyme supplements.
3Reliability
If comprehensive enzyme blend is used, then all DOMS symptoms are addressed effectively, but the formulation complexity increases
Solution Approach 1:
The patent merges five different digestive enzymes into a single integrated formulation, achieving comprehensive symptom relief without requiring multiple separate supplements. This consolidation maintains formulation simplicity while addressing all DOMS symptoms through the combined action of protease, amylase, lipase, cellulase, and lactase.
Solution Approach 2:
The single enzyme blend formulation achieves universal applicability by addressing multiple DOMS symptoms simultaneously through its multi-functional enzyme composition. This approach provides comprehensive symptom relief without increasing formulation complexity, as all five enzymes are delivered in one convenient supplement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The enzyme blend significantly reduces muscle soreness, tenderness, and inflammation, as evidenced by statistical significance in grip strength, pain scores, and muscle flexibility improvements, with no adverse effects, demonstrating improved therapeutic management of DOMS.
Implementation Method 1
Protease - 6000 PC/g (Protease Unit on L-tyrosine basis/gram)
Implementation Method 2
Alpha-amylase - 24000 DU/g (Dextrinizing Unit /gram)
Implementation Method 3
Lipase - 200 FlP/g (Fédération Internationale Pharmaceutique Unit/gram)
Implementation Method 4
Cellulase - 1100 CU/g (Cellulase Unit/gram)
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention discloses a combination of digestive enzymes (Protease, Amylase, Lactase, Lipase, Cellulase) - DigeZyme® for the therapeutic management - of delayed onset muscle soreness (DOMS).